Monogram Orthopaedics Q1 net loss $3.5M; 510(k) submission on track for H2 2024

Monogram Technologies Inc.

2024-Q1 EPS reported -$0.11

Net loss $3.5M in Q1 2024 vs $3.9M prior year; cash $10.1M at Mar 31.
Verification & validation testing expected largely complete in Q2 2024.
FDA 510(k) submission for mBôs TKA system planned for second half of 2024.
Engaged contract research organization for OUS clinical trial activities.
R&D expenses $2.4M, up from $1.9M, driven by V&V and mVision development.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Monogram Technologies Inc. reported the first quarter ended March 31, 2024 results: net income Net loss was $3.5 million.

Period: the first quarter ended March 31, 2024
Net income: Net loss was $3.5 million
Result: reported results

Exact text from the filing

On May 14, 2024, Monogram Orthopaedics Inc., a Delaware corporation (the “Company”) issued a press release announcing, among other things, its financial results for the three months ended March 31, 2024.

View on SEC.gov

Browse all earnings releases →

Source: SEC EDGAR

accession 0001104659-24-060937

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.